|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers 显示文摘 | Mallikaarjun S Salazar DE Bramer SL | 2004 | J Clin Pharmacol2004，44，2： | 1 |
| 2 | Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics显示文摘 | Bramer SL Forbes WP | 1999 | Clin Pharmacokinet1999，37，2： | 1 |
| 3 | Determination of cilostazol and its metabolites in human urine by high performance liquid chromatography显示文摘 | Tata PN Fu CH Bramer SL | 2001 | J Pharm BiomedAnal2001，24，： | 1 |
| 4 | Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers显示文摘 | Mallikaarjun S Salazar DE Bramer SL | 2004 | J Clin Pharmacol2004，44，2： | 1 |
| 5 | Cilostazol Pharmacokinetics after Single and Multiple Oral Doses in Healthy Males and Patients with Intermittent Claudication Resulting from Peripheral Arterial Disease显示文摘 | Bramer SL Forbes WP Mallikaarjun S | 1999 | Clinical Pharmacokinet1999，37，2： | 1 |
| 6 | Determination of cilostazol and its metabolites in human urine by high performance liquid chromatography显示文摘 | Tata PN Fu CH Bramer SL | 2001 | J Pharm Biomed Anal2001，24，3： | 1 |
| 7 | Determination of cilostazol and its metabolites in human urine by high performance liquid chromatography显示文摘 | Tata PN Fu CH Bramer SL | 2001 | J Pharm Biomed Anal2001，24，3： | 1 |
| 8 | Pharmacokinetics, tolerability,and safety of aripiprazole following multiple oral dosing in normal healthy volunteers显示文摘 | Mallikaarjun S Salazar DE Bramer SL | 2004 | J Clin Pharmacol2004，44，2： | 1 |
| 9 | Pharmacokinetics,tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers显示文摘 | Mallikaarjun S Salazar DE Bramer SL | 2004 | J Clin Pharmacol2004，44，2： | 1 |
| 10 | Pharmacokinetic and phar- macodynamie interaction between tolvaptan, a non - peptide AVP an- tagonist, and furosemide orhydroehlorotbiazide 显示文摘 | Shoal SE Bramer SL Bricmont P | 2007 | J Cardiovasc Pharmacol2007，50，： | 1 |
| 11 | Determination of cilostazol and its metabolites in human urine by high performance liquid chromatography显示文摘 | Tata PN Fu CH Bramer SL | 2001 | J Pharm Biomed Anal2001，24，3： | 1 |
| 12 | Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers显示文摘 | Mallikaarjun S Salazar DE Bramer SL | 2004 | J Clin Pharmacol2004，44，： | 1 |
| 13 | Determination of cilostazol and its metabolites in human urine by high performance liquid chromatography显示文摘 | Tata PN Fu CH Bramer SL | 2001 | J Pharm Biomed Anal2001，24，3： | 1 |
| 14 | Method for the quantitative analysis of cilostazol and its metabolites in human plasma using LC/MS/MS显示文摘 | BRAMER SL TATA PN VENGURLEKAR SS | 2001 | J Pharm Biomed Anal2001，26，4： | 1 |
| 15 | Pharmacoki netics, tolerability, and safety of aripiprazole fol lowing multiple oral dosing in normal healthy volun teers显示文摘 | Mallikaarjun S Salazar DE Bramer SL | 2004 | J Clin Pharmacol2004，44，2： | 1 |
| 16 | Determination of cilostazol and its metabolites in human urine by high performance liquid chromatography 显示文摘 | Fu CH Bramer SL | 2001 | J Pharm Biomed Anal2001，24，3： | 1 |
| 17 | Simultaneous quantitative determination of cilostazol and its metabolitesin human plasma by high-performance liquid chromatography 显示文摘 | Tara PN Okada K Akiyama H Bramer SL | 1999 | J Pharm Biomed Anal1999，728，2： | 1 |
| 18 | Pharma cokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furo- semide or hydrochlorothiazide 显示文摘 | Shoal SE Bramer SL Bricmont P | 2007 | J Cardiovasc Pharmacol2007，50，2： | 1 |
| 19 | Pharmacokinet ics,tolerability,and safety of aripiprazole following multiple oral dosing in normal healthy volunteers显示文摘 | MALLIKAARJUN S SALAZAR DE BRAMER SL | 2004 | J Clin Pharmacol2004，44，2： | 1 |
| 20 | Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males 显示文摘 | Efthymiopoulos C Bramer SL Maroli A | 1997 | Clin Pharmacokinet1997，33，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员